Cargando…

Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study

Background. Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained. Objective. To assess effect of Litramine on maintenance of body weight loss. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grube, Barbara, Chong, Pee-Win, Alt, Felix, Uebelhack, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576018/ https://www.ncbi.nlm.nih.gov/pubmed/26435849 http://dx.doi.org/10.1155/2015/953138

Ejemplares similares

A Review of the Efficacy and Safety of Litramine IQP-G-002AS, an Opuntia ficus-indica Derived Fiber for Weight Management
por: Chong, Pee-Win, et al.
Publicado: (2014)

Evaluation of Benefit and Tolerability of IQP‐CL‐101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double‐Blinded, Randomised, Placebo‐Controlled Clinical Trial
por: Alt, Felix, et al.
Publicado: (2017)

Sleep Promoting Effects of IQP-AO-101: A Double-Blind, Randomized, Placebo-Controlled Exploratory Trial
por: Bongartz, Udo, et al.
Publicado: (2019)

IQP-GC-101 Reduces Body Weight and Body Fat Mass: A Randomized, Double-Blind, Placebo-Controlled Study
por: Chong, Pee-Win, et al.
Publicado: (2014)

Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study
por: Bongartz, Udo, et al.
Publicado: (2021)

Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
por: Uebelhack, Ralf, et al.
Publicado: (2019)

Erratum to “Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects”
por: Uebelhack, Ralf, et al.
Publicado: (2019)

Effects of Cactus Fiber on the Excretion of Dietary Fat in Healthy Subjects: A Double Blind, Randomized, Placebo-Controlled, Crossover Clinical Investigation
por: Uebelhack, Ralf, et al.
Publicado: (2014)

Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study
por: Peng, Li Vern, et al.
Publicado: (2022)

IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety
por: Grube, Barbara, et al.
Publicado: (2015)

Corrigendum to “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety”
por: Grube, Barbara, et al.
Publicado: (2016)

A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study
por: Grube, Barbara, et al.
Publicado: (2013)

In Vitro and Ex Vivo Evaluations on Transdermal Delivery of the HIV Inhibitor IQP-0410
por: Ham, Anthony S., et al.
Publicado: (2013)

O002 Medical therapy for sleep disordered breathing in children: a randomised, double-blind placebo-controlled trial
por: Baker, A, et al.
Publicado: (2021)

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
por: Ringman, John M, et al.
Publicado: (2012)

Effects of aged garlic extract on arterial elasticity in a placebo-controlled clinical trial using EndoPAT™ technology
por: Gruenwald, Joerg, et al.
Publicado: (2020)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study
por: Shirai, Kohji, et al.
Publicado: (2018)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
por: Turner, Alyna, et al.
Publicado: (2019)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)
por: Ellegaard, Pernille Kempel, et al.
Publicado: (2018)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
por: Prins, Niels D., et al.
Publicado: (2021)

LBODP044 Effects Of Dietary Supplementation On Progression To Type 2 Diabetes Single Center Randomized Double-blind Placebo-controlled Trial An Interim Analysis At 24 Weeks
por: Chattieng, Preeyapat, et al.
Publicado: (2022)

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
por: Cefalu, William T., et al.
Publicado: (2015)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Reduced muscular fatigue after a 12-week leucine-rich amino acid supplementation combined with moderate training in elderly: a randomised, placebo-controlled, double-blind trial
por: Reule, Claudia A, et al.
Publicado: (2017)

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
por: Kim, Sin Gon, et al.
Publicado: (2014)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
por: Berk, Michael, et al.
Publicado: (2012)

A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State
por: Patkar, Ashwin, et al.
Publicado: (2012)

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis
por: Burgos-Vargas, Rubén, et al.
Publicado: (2022)

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
por: Mease, P J, et al.
Publicado: (2014)

Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
por: McElhaney, Janet E., et al.
Publicado: (2011)

ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
por: Klose, Marianne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aep2m0klj0la7pvcs7au74lfsm